2265.3000 -17.70 (-0.78%)
NSE Oct 13, 2026 15:31 PM
Volume: 260.0K
 

2265.30
-0.78%
Deven Choksey
We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 16.8% / 86.1% / 111.8% for the period of FY26-FY28.
Glenmark Pharmaceuticals Ltd. is trading above its 200 day SMA of 2211.1
More from Glenmark Pharmaceuticals Ltd.
Recommended